Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025 0.1% Revenue growth, 20253 Where the money goes Where each dollar of revenue went, fiscal 2025 Research and development
Research and development 100¢ $28.5M Out of $7.7M in revenue.3
Financial statements
Income statement Balance sheet Cash flow
Annual Quarterly
Revenue4 5 6 7 3 $7.7M in 2025+3231% since 2020 0 $2.0M $4.0M $6.0M $8.0M 2020: $231.0K $231.0K 2020 2021: $1.3M $1.3M 2021 +445% 2022: $5.7M $5.7M 2022 +355% 2023: $7.9M $7.9M 2023 +37% 2024: $7.7M $7.7M 2024 −2% 2025: $7.7M $7.7M 2025 +0% Operating income4 5 6 7 3 -$36.1M in 2025−27% since 2020 -$100.0M -$75.0M -$50.0M -$25.0M 0 2020: -$49.2M -$49.2M 2020 2021: -$92.8M -$92.8M 2021 +89% 2022: -$90.3M -$90.3M 2022 −3% 2023: -$76.2M -$76.2M 2023 −16% 2024: -$73.0M -$73.0M 2024 −4% 2025: -$36.1M -$36.1M 2025 −51% Net income4 5 6 7 3 -$33.4M in 2025−45% since 2020 -$100.0M -$75.0M -$50.0M -$25.0M 0 2020: -$60.7M -$60.7M 2020 2021: -$98.6M -$98.6M 2021 +62% 2022: -$88.1M -$88.1M 2022 −11% 2023: -$69.2M -$69.2M 2023 −21% 2024: -$63.1M -$63.1M 2024 −9% 2025: -$33.4M -$33.4M 2025 −47% Revenue8 9 $5.0K in Q2 FY2026−81% since Q1 FY2026 0 $10.0K $20.0K $30.0K Q1 FY2026: $26.0K $26.0K Q1 FY2026 Q2 FY2026: $5.0K $5.0K Q2 FY2026 −81% Operating income8 9 -$8.4M in Q2 FY2026+10% since Q1 FY2026 -$10.0M -$7.5M -$5.0M -$2.5M 0 Q1 FY2026: -$7.6M -$7.6M Q1 FY2026 Q2 FY2026: -$8.4M -$8.4M Q2 FY2026 +10% Net income8 9 -$7.7M in Q2 FY2026+7% since Q1 FY2026 -$8.0M -$6.0M -$4.0M -$2.0M 0 Q1 FY2026: -$7.2M -$7.2M Q1 FY2026 Q2 FY2026: -$7.7M -$7.7M Q2 FY2026 +7% Fiscal year 2019 2020 2021 2022 2023 2024 2025 Revenue $231.0K4 $1.3M5 $5.7M6 $7.9M7 $7.7M3 $7.7M3 Research and development $40.4M4 $75.7M5 $73.1M6 $61.5M7 $57.5M3 $28.5M3 Operating income -$49.2M4 -$92.8M5 -$90.3M6 -$76.2M7 -$73.0M3 -$36.1M3 Income tax $04 $05 $06 $07 $03 $03 Net income -$60.7M4 -$98.6M5 -$88.1M6 -$69.2M7 -$63.1M3 -$33.4M3 Earnings per share -$2.975 -$2.366 -$1.837 -$33.063 -$17.853 Earnings per share (diluted) -$2.975 -$2.366 -$1.837 -$33.063 -$17.853
Total assets4 5 6 7 3 $56.7M in 2025+22% since 2020 0 $100.0M $200.0M $300.0M $400.0M 2020: $46.5M $46.5M 2020 2021: $307.7M $307.7M 2021 +561% 2022: $227.8M $227.8M 2022 −26% 2023: $159.8M $159.8M 2023 −30% 2024: $99.6M $99.6M 2024 −38% 2025: $56.7M $56.7M 2025 −43% Total liabilities4 5 6 7 3 $30.2M in 2025−35% since 2020 0 $20.0M $40.0M $60.0M 2020: $46.2M $46.2M 2020 2021: $57.6M $57.6M 2021 +25% 2022: $56.3M $56.3M 2022 −2% 2023: $47.0M $47.0M 2023 −16% 2024: $42.4M $42.4M 2024 −10% 2025: $30.2M $30.2M 2025 −29% Shareholders’ equity4 5 6 7 3 $26.5M in 2025-$200.0M -$100.0M 0 $100.0M $200.0M $300.0M 2019: -$45.8M -$45.8M 2019 2020: -$104.9M -$104.9M 2020 +129% 2021: $250.1M $250.1M 2021 2022: $171.5M $171.5M 2022 −31% 2023: $112.7M $112.7M 2023 −34% 2024: $57.2M $57.2M 2024 −49% 2025: $26.5M $26.5M 2025 −54% Cash4 5 6 7 3 $11.7M in 2025+111% since 2020 0 $10.0M $20.0M $30.0M 2020: $5.5M $5.5M 2020 2021: $27.4M $27.4M 2021 +394% 2022: $9.2M $9.2M 2022 −66% 2023: $10.8M $10.8M 2023 +17% 2024: $7.2M $7.2M 2024 −33% 2025: $11.7M $11.7M 2025 +62% Total assets8 9 $40.3M in Q2 FY2026−29% since Q1 FY2025 0 $20.0M $40.0M $60.0M Q1 FY2025: $56.7M $56.7M Q1 FY2025 Q2 FY2025: $56.7M $56.7M Q2 FY2025 +0% Q1 FY2026: $48.0M $48.0M Q1 FY2026 −15% Q2 FY2026: $40.3M $40.3M Q2 FY2026 −16% Total liabilities8 9 $27.7M in Q2 FY2026−8% since Q1 FY2025 0 $10.0M $20.0M $30.0M $40.0M Q1 FY2025: $30.2M $30.2M Q1 FY2025 Q2 FY2025: $30.2M $30.2M Q2 FY2025 +0% Q1 FY2026: $28.2M $28.2M Q1 FY2026 −7% Q2 FY2026: $27.7M $27.7M Q2 FY2026 −2% Shareholders’ equity8 9 $12.6M in Q2 FY2026−52% since Q1 FY2025 0 $10.0M $20.0M $30.0M Q1 FY2025: $26.5M $26.5M Q1 FY2025 Q2 FY2025: $26.5M $26.5M Q2 FY2025 +0% Q1 FY2026: $19.8M $19.8M Q1 FY2026 −25% Q2 FY2026: $19.8M $19.8M Q2 FY2026 +0% Q2 FY2026: $12.6M $12.6M Q2 FY2026 −36% Cash8 9 $12.9M in Q2 FY2026+10% since Q1 FY2025 0 $5.0M $10.0M $15.0M Q1 FY2025: $11.7M $11.7M Q1 FY2025 Q2 FY2025: $11.7M $11.7M Q2 FY2025 +0% Q1 FY2026: $11.6M $11.6M Q1 FY2026 −1% Q2 FY2026: $12.9M $12.9M Q2 FY2026 +11% Fiscal year 2019 2020 2021 2022 2023 2024 2025 Cash $5.5M4 $27.4M5 $9.2M6 $10.8M7 $7.2M3 $11.7M3 Current assets $25.4M4 $189.2M5 $172.7M6 $105.7M7 $50.8M3 $30.3M3 Total assets $46.5M4 $307.7M5 $227.8M6 $159.8M7 $99.6M3 $56.7M3 Current liabilities $11.3M4 $21.3M5 $23.1M6 $20.5M7 $15.9M3 $8.4M3 Total liabilities $46.2M4 $57.6M5 $56.3M6 $47.0M7 $42.4M3 $30.2M3 Shareholders’ equity -$45.8M4 -$104.9M5 $250.1M6 $171.5M7 $112.7M3 $57.2M3 $26.5M3 Shares outstanding 2.1M shares4 37.4M shares5 37.8M shares6 38.1M shares7 1.9M shares3 1.9M shares3
Cash from operations4 5 6 7 3 -$39.9M in 2025−16% since 2020 -$80.0M -$60.0M -$40.0M -$20.0M 0 2020: -$47.3M -$47.3M 2020 2021: -$57.1M -$57.1M 2021 +21% 2022: -$76.5M -$76.5M 2022 +34% 2023: -$69.5M -$69.5M 2023 −9% 2024: -$61.3M -$61.3M 2024 −12% 2025: -$39.9M -$39.9M 2025 −35% Capital spending4 5 6 7 3 $72.0K in 2025−98% since 2020 0 $1.0M $2.0M $3.0M $4.0M 2020: $3.3M $3.3M 2020 2021: $2.3M $2.3M 2021 −28% 2022: $2.0M $2.0M 2022 −16% 2023: $206.0K $206.0K 2023 −89% 2024: $41.0K $41.0K 2024 −80% 2025: $72.0K $72.0K 2025 +76% Free cash flow4 5 6 7 3 -$39.9M in 2025−21% since 2020 -$80.0M -$60.0M -$40.0M -$20.0M 0 2020: -$50.6M -$50.6M 2020 2021: -$59.4M -$59.4M 2021 +17% 2022: -$78.5M -$78.5M 2022 +32% 2023: -$69.7M -$69.7M 2023 −11% 2024: -$61.3M -$61.3M 2024 −12% 2025: -$39.9M -$39.9M 2025 −35% Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Fiscal year 2019 2020 2021 2022 2023 2024 2025 Cash from operations -$47.3M4 -$57.1M5 -$76.5M6 -$69.5M7 -$61.3M3 -$39.9M3 Capital spending $3.3M4 $2.3M5 $2.0M6 $206.0K7 $41.0K3 $72.0K3 Free cash flow -$50.6M -$59.4M -$78.5M -$69.7M -$61.3M -$39.9M
Compare Bolt Biotherapeutics, Inc. with another company
Former names
Bolt Therapeutics, Inc. May 7, 2015 to May 7, 20152
Recent filings
Oct 6, 2026 8-K Sep 21, 2026 4 Sep 21, 2026 4 Sep 21, 2026 4 Aug 13, 2026 SCHEDULE 13G Aug 11, 2026 8-K Aug 11, 2026 10-Q Jun 11, 2026 8-K Jun 11, 2026 4 Jun 11, 2026 4 Jun 11, 2026 4 Jun 11, 2026 4 Jun 11, 2026 4 May 12, 2026 8-K May 12, 2026 10-Q Every filing from the last three years, summarized . The full record is on SEC EDGAR.1
